AR007747A1 - Inhibidores del reflujo - Google Patents

Inhibidores del reflujo

Info

Publication number
AR007747A1
AR007747A1 ARP970104051A ARP970104051A AR007747A1 AR 007747 A1 AR007747 A1 AR 007747A1 AR P970104051 A ARP970104051 A AR P970104051A AR P970104051 A ARP970104051 A AR P970104051A AR 007747 A1 AR007747 A1 AR 007747A1
Authority
AR
Argentina
Prior art keywords
reflux inhibitors
reflux
inhibitors
gaba
inhibition
Prior art date
Application number
ARP970104051A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20403936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR007747(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR007747A1 publication Critical patent/AR007747A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se relaciona con el uso de agonistas de los receptores GABA (B) para la inhibición de las relajaciones transitorias del esfínter esofágico inferior, ypara el tratamiento de la enfermedad de reflujo gastroesofágico.
ARP970104051A 1996-09-18 1997-09-04 Inhibidores del reflujo AR007747A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603408A SE9603408D0 (sv) 1996-09-18 1996-09-18 Medical use

Publications (1)

Publication Number Publication Date
AR007747A1 true AR007747A1 (es) 1999-11-10

Family

ID=20403936

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104051A AR007747A1 (es) 1996-09-18 1997-09-04 Inhibidores del reflujo

Country Status (34)

Country Link
US (2) US6117908A (es)
EP (2) EP1344524B1 (es)
JP (1) JP4098832B2 (es)
KR (2) KR100568659B1 (es)
CN (1) CN1117560C (es)
AR (1) AR007747A1 (es)
AT (2) ATE334700T1 (es)
AU (1) AU714370B2 (es)
BR (1) BR9711400A (es)
CA (1) CA2265615C (es)
CZ (1) CZ299997B6 (es)
DE (2) DE69736445T2 (es)
DK (2) DK1344524T3 (es)
EE (1) EE03952B1 (es)
ES (2) ES2206749T3 (es)
HU (1) HU224968B1 (es)
ID (1) ID19621A (es)
IL (1) IL128961A (es)
IS (2) IS2329B (es)
MY (1) MY122020A (es)
NO (1) NO326837B1 (es)
NZ (2) NZ334495A (es)
PL (1) PL190028B1 (es)
PT (2) PT936906E (es)
RU (1) RU2199316C2 (es)
SA (1) SA97180522B1 (es)
SE (1) SE9603408D0 (es)
SI (2) SI0936906T1 (es)
SK (1) SK285744B6 (es)
TR (1) TR199900591T2 (es)
TW (1) TW548104B (es)
UA (1) UA61081C2 (es)
WO (1) WO1998011885A1 (es)
ZA (1) ZA977969B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
WO1999008670A1 (en) 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7319095B2 (en) 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
SE9904507D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
TWI256314B (en) * 2000-02-09 2006-06-11 Mitsubishi Pharma Corp Preventive-therapeutical medicament for gastroesophageal reflux disease
MXPA03011096A (es) * 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
SE0102057D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts I
AR033779A1 (es) * 2001-06-08 2004-01-07 Astrazeneca Ab Compuestos utiles en la enfermedad de reflujo
SE0102058D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts II
SE0102055D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Compounds
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
SE0201940D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0201939D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination
SE0201943D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New use
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
NZ540591A (en) * 2002-12-13 2008-03-28 Warner Lambert Co Pregabalin derivatives for the treatment of fibromyalgia and other disorders
BRPI0413756A (pt) 2003-08-20 2006-10-31 Xenoport Inc composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica
ATE546427T1 (de) * 2003-08-20 2012-03-15 Xenoport Inc Acyloxyalkylcarbamat-prodrugs, syntheseverfahren und anwendung
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
CN1849336A (zh) * 2003-09-12 2006-10-18 詹森药业有限公司 嵌合gabab受体
SG147437A1 (en) * 2003-10-14 2008-11-28 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
GB0327186D0 (en) * 2003-11-21 2003-12-24 Novartis Ag Organic compounds
US20050220863A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
US7494985B2 (en) * 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
US7566738B2 (en) * 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006071186A1 (en) * 2004-12-27 2006-07-06 Astrazeneca Ab Use of gabab receptor agonists
KR20080091452A (ko) * 2005-12-23 2008-10-13 아스트라제네카 아베 위장 장애의 치료를 위한 이미다졸 유도체
BRPI0620415A2 (pt) * 2005-12-23 2011-11-08 Astrazeneca Ab composto e sais farmaceuticamente e farmacologicamente aceitáveis do mesmo, e enantiÈmeros do composto e sais do mesmo, composição farmaceutica, e, uso de um composto opcionalmente em combinação com um agonista do receptor de gabab, e, métodos para o tratamento de doença, de um distúrbio, e de sìndrome
CA2632021A1 (en) 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
WO2007073299A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Imidazoles as gaba-b receptor modulators
CA2631991A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Heterocyclic gaba-b modulators
US7585996B2 (en) * 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EP2124884B1 (en) * 2006-12-22 2019-07-10 Ironwood Pharmaceuticals, Inc. Compositions comprising bile acid sequestrants for treating esophageal disorders
TWI369982B (en) * 2007-01-11 2012-08-11 Xenoport Inc Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
CA2682301A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab Xanthine compounds having a positive allosteric gabab receptor modulator effect
TW200908957A (en) * 2007-06-15 2009-03-01 Xenoport Inc Use of prodrugs of GABA analogs, antispasticity agents, and prodrugs of GABAB receptor agonists for treating spasticity
CN101743011A (zh) * 2007-07-25 2010-06-16 阿斯利康(瑞典)有限公司 (3-氨基-2-氟丙基)次膦酸用于治疗非糜烂性反流病的用途
US20090118365A1 (en) * 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
ES2601852T3 (es) * 2008-01-25 2017-02-16 Xenoport, Inc. Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
WO2009117160A2 (en) * 2008-03-20 2009-09-24 General Mills, Inc. Compound and method for treatment of gastroesophageal reflux
US7989641B2 (en) 2008-08-07 2011-08-02 Xenoport, Inc. Methods of synthesizing N-hydroxysuccinimidyl carbonates
US8299291B2 (en) * 2008-08-07 2012-10-30 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
KR20110117216A (ko) * 2009-03-03 2011-10-26 제노포트 인코포레이티드 Ｒ-바클로펜 전구약물의 서방형 경구 투약 형태
EP2419401A2 (en) * 2009-04-17 2012-02-22 XenoPort, Inc. GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
US8580850B2 (en) 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
WO2013180796A1 (en) 2012-06-01 2013-12-05 Lynn Health Science Institute, Inc. Methods for treating insomnia
EP3755314A1 (en) * 2018-02-22 2020-12-30 Diamyd Medical AB Gaba a receptor agonists for treatment of disorders influenced by dysfunction beta cells
TW202412754A (zh) * 2022-06-07 2024-04-01 瑞士商意梭凱普公司 應用於食道黏膜的包含逆流抑制劑的藥物傳遞系統

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004077A1 (en) * 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
NO882881L (no) * 1988-06-29 1990-01-02 Trond Nilsen Anordning for lengdekorrugering av metallplater.
GB8820266D0 (en) * 1988-08-26 1988-09-28 Smith Kline French Lab Compounds
WO1990009096A2 (en) * 1989-02-03 1990-08-23 Cambridge Neuroscience Research, Inc. Method of screening and classifying compounds
GB9117716D0 (en) * 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
ATE215365T1 (de) * 1992-01-22 2002-04-15 Glaxo Group Ltd Medizinische verwendung von atypischen beta- adrenoceptor agonisten
GB9408064D0 (en) * 1994-04-22 1994-06-15 Merck Sharp & Dohme Nucleic acids
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions

Also Published As

Publication number Publication date
DE69724809T2 (de) 2004-07-15
NZ334495A (en) 2000-09-29
ATE249212T1 (de) 2003-09-15
UA61081C2 (uk) 2003-11-17
NO991287D0 (no) 1999-03-17
KR20050101237A (ko) 2005-10-20
HU224968B1 (en) 2006-04-28
AU714370B2 (en) 1999-12-23
US6117908A (en) 2000-09-12
PL190028B1 (pl) 2005-10-31
DE69736445T2 (de) 2007-03-15
DE69724809D1 (de) 2003-10-16
KR20000036185A (ko) 2000-06-26
SE9603408D0 (sv) 1996-09-18
PT936906E (pt) 2003-12-31
WO1998011885A1 (en) 1998-03-26
JP4098832B2 (ja) 2008-06-11
SK285744B6 (sk) 2007-07-06
ID19621A (id) 1998-07-23
SK30599A3 (en) 2000-01-18
NO991287L (no) 1999-03-17
CZ93099A3 (cs) 1999-09-15
MY122020A (en) 2006-03-31
NO326837B1 (no) 2009-02-23
IL128961A0 (en) 2000-02-17
ATE334700T1 (de) 2006-08-15
DE69736445D1 (de) 2006-09-14
SI1344524T1 (sl) 2006-12-31
EE03952B1 (et) 2003-02-17
DK1344524T3 (da) 2006-10-30
EP0936906B1 (en) 2003-09-10
IS5001A (is) 1999-03-15
RU2199316C2 (ru) 2003-02-27
HUP9903825A3 (en) 2001-06-28
ES2206749T3 (es) 2004-05-16
BR9711400A (pt) 1999-08-17
ES2268227T3 (es) 2007-03-16
AU4406497A (en) 1998-04-14
PL332497A1 (en) 1999-09-13
EP0936906A1 (en) 1999-08-25
IL128961A (en) 2004-08-31
SA97180522B1 (ar) 2006-04-04
HK1057004A1 (en) 2004-03-12
KR100568659B1 (ko) 2006-04-07
CA2265615C (en) 2007-01-30
EP1344524A1 (en) 2003-09-17
JP2001501604A (ja) 2001-02-06
KR100553294B1 (ko) 2006-02-22
IS2538B (is) 2009-09-15
CN1117560C (zh) 2003-08-13
ZA977969B (en) 1998-03-18
CA2265615A1 (en) 1998-03-26
DK0936906T3 (da) 2003-11-24
CZ299997B6 (cs) 2009-01-14
SI0936906T1 (en) 2004-02-29
HK1022100A1 (en) 2000-07-28
IS8623A (is) 2007-03-19
HUP9903825A2 (hu) 2001-05-28
PT1344524E (pt) 2006-11-30
IS2329B (is) 2008-01-15
TW548104B (en) 2003-08-21
US6664069B1 (en) 2003-12-16
TR199900591T2 (xx) 1999-07-21
NZ504244A (en) 2000-09-29
EP1344524B1 (en) 2006-08-02
CN1237105A (zh) 1999-12-01
EE9900095A (et) 1999-10-15

Similar Documents

Publication Publication Date Title
AR007747A1 (es) Inhibidores del reflujo
EA200300105A1 (ru) Нестероидные ингибиторы воспалений
ES2486866T3 (es) Dispositivo ortopédico para corregir posiciones defectuosas de los dedos del pie
CY2607B2 (en) Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanylcyclyse agonists
EA200200208A1 (ru) Синергитическая композиция
AR031130A1 (es) N-acilsulfonamidas promotoras de la apoptosis
CU23029A3 (es) Analogos sustituidos del benzopirano para el tratamiento de la inflamacion
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
AR023777A1 (es) Nuevos compuestos
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
ES2172579T3 (es) Agonistas/antagonistas de estrogenos.
DE69916792D1 (de) Kaliumkanalblocker
ATE250571T1 (de) Kaliumkanal-blocker
HN2001000217A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
CY1105125T1 (el) Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων
CL2007001176A1 (es) Compuestos derivados de piridina-triazol-pirrolidina, moduladores del receptor de glutamato metabotropico (mglur5); composiciones farmaceuticas que los contienen; combinacion de ellos con un agente inhibidor de la secrecion acida; intermediarios; y su uso trastornos neurologicos,psiquiatricos, gastrointestinales y otros.
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
PA8467301A1 (es) Nuevos derivados del acido dihidroxihexanoico
BR0011801A (pt) Inibidores de benzamida substituìda para 3c protease de rinovìrus
BR0112355A (pt) Uso de inibidores da proteìna egf-r tirosina cinase para a prevenção do fotoenvelhecimento da pele humana
ATE322492T1 (de) Nicht-nukleosid reverse transkriptase inhibitoren
ECSP034604A (es) Inhibicion de la dependendia de celulas tumorales del factor de crecimiento
AR046672A1 (es) Prevencion y tratamiento de enfermedaes cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,6(10)-trien-3,16alfa-diol
IT1306165B1 (it) Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.

Legal Events

Date Code Title Description
FB Suspension of granting procedure